About: Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 28 June 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) bài báo khoa học (vi) artículu científicu espublizáu en xunu de 2019 (ast) scientific article published on 28 June 2019 (en) наукова стаття, опублікована 28 червня 2019 (uk)
publication date	wds:Q93103375-DCCE871C-82BC-4ACE-ACAC-5C85A8282153
publication date	2019-06-28 00:00:00Z (xsd:dateTime)
cites work	wds:Q93103375-0F767C82-336B-48AC-9C0F-45DE64D64EFF wds:Q93103375-196B1690-3896-486D-8D30-AD6F5D242099 wds:Q93103375-1CB43884-B1B7-4739-B9A1-F94283C00AAB wds:Q93103375-20F9598D-F2A0-47EC-A811-9EE16E1356A7 wds:Q93103375-3019C251-183F-4AE7-84FB-CA7FD9F18507 wds:Q93103375-38E3EA41-7BD0-49C3-B313-6EAB7C26ADCA wds:Q93103375-403D7B13-BE92-4990-9E75-DB7520014E1F wds:Q93103375-41BE130B-CC2C-4E81-BC62-782EBD9857C4 wds:Q93103375-471DDD9D-3795-4D7C-AC3A-72A092062947 wds:Q93103375-5E7B77F5-BBF4-472B-92A1-A65754E0383C wds:Q93103375-854B6A13-63A3-4C32-918A-1BF6BCA65E9D wds:Q93103375-8E0321A2-614F-430B-A878-50AB25748A28 wds:Q93103375-9443B197-6FEC-41A0-A62D-38093CAB3AF1 wds:Q93103375-945041C8-3B5E-4AF4-A74C-BB58DB653088 wds:Q93103375-97B640D0-AA0E-4074-8F5B-3766B056D1E5 wds:Q93103375-97E66A0F-9CA5-43D5-B99B-E9A6727C376B wds:Q93103375-A716A60A-D871-4FE9-B640-737C86FF743D wds:Q93103375-A7B41610-6BBD-451C-86D2-6F151EC67F79 wds:Q93103375-ABCDD7AA-D39D-459D-BBA0-BF72891039AD wds:Q93103375-AD527228-9971-4B51-AF44-4F5CF46EBB90 wds:Q93103375-B6ECE6DF-542E-49BE-A96C-5473D0C13CA1 wds:Q93103375-B867F9E5-B522-4E73-853D-19B3AC31DBAD wds:Q93103375-C9451F09-5A9A-4069-9438-83299C04221E wds:Q93103375-D9035E97-E28E-4A59-BB61-6CC10563104A wds:Q93103375-E3BBC9F0-7664-4564-A1C9-75DA0478834D wds:Q93103375-E8CE8A3E-2E5F-4D08-AA04-9DCF5243A6E5 wds:Q93103375-EE886A6B-F244-4BB2-AC04-C1BAAE6C6F86 wds:Q93103375-F4CC841B-FB3C-435A-A477-7AE97FF081EA wds:Q93103375-F97CF53B-C044-4E12-B81D-BCE4EFE4E6B3 wds:Q93103375-FA007B87-4B9B-4AB9-BFF4-503217E03845
cites work	Effective drug delivery by PEGylated drug conjugates Geographic atrophy: clinical features and potential therapeutic approaches PEGylation of therapeutic proteins Causes of vision loss worldwide, 1990-2010: a systematic analysis Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results Ocular drug delivery UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients. Review: practical issues in intravitreal drug delivery Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review The experimental and clinical use of intravitreal antibiotics to treat bacterial and fungal endophthalmitis Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab. Impact of polymer geometry on the interactions of protein-PEG conjugates. Safety Assessment of Formulation Vehicles Following Intravitreal Administration in Rabbits Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration Visual impairment certification secondary to ARMD in Leeds, 2005-2010: is the incidence falling? Trehalose limits BSA aggregation in spray-dried formulations at high temperatures: implications in preparing polymer implants for long-term protein delivery Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye. Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal Biologics
author name string	wds:Q93103375-3A5EE35A-9439-4C13-8620-EB81425AA4E4 wds:Q93103375-3CEEF505-3817-4D16-BFA0-A6814F85102E wds:Q93103375-7B59A6A2-BF30-4485-8D84-9DA5BEDB1A40 wds:Q93103375-8EDD5254-15F4-43AA-B9AD-794191A6981B wds:Q93103375-A00C0AD4-C1B1-46C8-B6B4-64BB3D94125C wds:Q93103375-A0854BE3-5E19-4F2E-B171-DB8835B0E9B0 wds:Q93103375-A5DDB1F0-3287-4328-A0FF-D7185557593C wds:Q93103375-C23C5BDB-DE37-45EB-BDB2-7BDD9F107C43 wds:Q93103375-C7702449-B8CF-4597-9B58-A8839192165C wds:Q93103375-D4F1E56F-9FF7-4F7D-A7FB-4AC6841C6B4B wds:Q93103375-E9A7D4AF-751D-4069-8D0C-C0DC3C4E80C9 wds:Q93103375-F0B659E1-16FF-4926-A305-8B784BBE632A
author name string	Robert F Kelley Amrita Kamath Philip E Hass Wendy Sandoval Vladimir Bantseev Justin M Scheer Maciej T Paluch Helen Booler Susan Crowell Craig Blanchette Ashley Morando Nikhil Peer
rdfs:label	Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye (en) Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye (nl)
skos:prefLabel	Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye (en) Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye (nl)
name	Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye (en) Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye (nl)
author	wds:Q93103375-6AB33D35-18AB-4DB5-95B8-8D2FB8787C2F wds:Q93103375-6D219717-E701-402E-8FDC-EE2DF5F59CBD

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software